Alliance Study Shows Some Patients with Locally Advanced Rectal Cancer Can Safely Avoid Radiation Therapy

June 5, 2023

Patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery based on the findings of the phase III Alliance PROSPECT (N1048) trial presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in the New England Journal of Medicine (effi

Alliance/NCTN/NCORP/AFT at 2023 ASCO     

May 25, 2023

The 59th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene June 2-6, bringing together thousands of oncology professionals from around the world in person. This year's meeting theme is "Partnering with Patients: The Cornerstone of Cancer Care and Research." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to

New Trial Alert: Alliance A012103 Triple Negative Breast Cancer

May 10, 2023

Alliance A012103: OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy

Overview: Sara Tolaney, MD, Dana-Farber Cancer Institute, leads this phase III trial that compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a patholo

Older News